Pricing and Reimbursement

Ritva joined Medaffcon’s team in March 2018. Before this, she had worked for almost six years at Farenta in corresponding tasks, providing pharmaceutical companies with strategic consultation and expert assistance related to Market Access functions. In addition, Ritva holds more than 20 years of experience in the pharmaceutical industry, where she has worked as a Market Access Manager at Sanofi (12 years), as a Regulatory Affairs Manager at Bayer and as a Researcher in Pharmaceutical Product Development at Orion.

In the pharmaceutical industry, Ritva is interested in Market Access issues particularly due to their diversity and societal impact. “Market Access is a great observational spot to view the development of new innovative medicinal treatment, aiming to improve patients’ treatment in its entirety. I consider it important to increase cooperation between different actors in the pharmaceutical industry and to find such new solution models that make effective treatment optimally available for patients without raising society’s costs unreasonably“.

Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry, he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.

Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment.

“From an access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole”.

Heini joined Medaffcon’s Market Access team in May 2018. She has graduated in Health Economics from the University of Eastern Finland, and her master’s thesis discusses risk-sharing agreements in the pharmaceutical market.

Heini is interested in the changes occurring in the pharmaceutical and healthcare industries as well as in the possibilities of Health Economics in assessing the methods and economic resources in the field. Heini’s assets include her state-of-the-art theoretical knowledge in the field of Health Economics, combined with practice- and patient-oriented thinking.

Jenni joined Medaffcon’s team in March 2020. She has a Master’s degree in Pharmacy and in Toxicology and also PhD in Pharmacy. Jenni’s dissertation in the University of Eastern Finland in Kuopio Campus was about the role of placenta in fetal toxicity of chemicals. While doing her PhD, Jenni has been working in Farenta as pricing and reimbursement specialist. Jenni has over 10 years of experience in Market Access of Pharma Industry.

”It’s great to help Pharma companies in the Market Access of new products. In the field of Market Access you can truly see how new drug treatments become available to patients. In my current position, I am able to utilize my diverse skills, which I have accumulated through both my education and my job.”

Lotta joined Medaffcon in spring 2017. She holds a master’s degree in Health Sciences, with Health Economics as her major. In her master`s thesis, Lotta analyzed how real-world data can be utilized in the assessment of drug costs. Lotta worked at Orion during her studies. 

Lotta brings to Medaffcon`s team her expertise in Health Economics that she applies in health technology assessments and price and reimbursement processes. 

In the field, Lotta`s special interests are working for the benefit of patients and how health economic information is utilized in health care decision making. “I believe that knowledge of health economics and the need for health economic information will play an increasingly important role in future health care”. 

Triin joined Medaffcon´s health economic team in April 2015. Triin´s main field of responsibilities are health economic and pharmaceuticals market access related projects, for example, health economic evaluations and price and reimbursement applications. During her consultant career at Medaffcon, Triin has also been an in-house consultant for one pharma company in the role of Market Access Manager for almost two years. 

Triin has a Master of Science degree, majoring in Health Economics, and a degree as a registered nurse. Triin has previous work experience from the pharmaceutical industry in the Market Access function and from an operating theatre in the public sector. 

“It´s great to be involved in the constantly developing field of health care and market access, such as conditional reimbursement, risk-sharing agreements at hospitals, and HTAs, to mention just a few examples. The best thing about my job is to promote the use of cost-effective health care technologies”.

Tatu joined Medaffcon in the fall of 2016. Tatu holds two master’s degrees, majoring in Marketing and Health Economics. Before joining Medaffcon, he worked in the pharmaceutical industry at Boehringer Ingelheim as an Account Manager. At Medaffcon, Tatu works mainly with health technology assessments and is the access & health economics team lead. Through his educational and professional background, Tatu has a wide range of expertise in the pharmaceutical industry and understands the needs of each function.

Tatu’s strength is his comprehensive understanding of the pharmaceutical industry and healthcare environment. Tatu is particularly interested in the possibility to turn data into understandable information to support healthcare decision-making.

“I love the hype around the utilization of real-world effectiveness and cost-effectiveness data. Now we need steps to include the data as a systematic part of the decision-making process, which allows the optimal allocation of resources”.